Abnova (Taiwan) Corporation — Investor Relations & Filings
Abnova Corporation is a global leader in the high-throughput production of antibodies and recombinant proteins. By integrating industrial-scale manufacturing with IT-driven management systems, the company maintains one of the world's largest catalogs of biological reagents. Its core offerings encompass gene synthesis, cytogenetics, peptide services, and protein expression. Abnova provides comprehensive solutions for life science research, including custom antibody production, scale-up, and humanization. Recent technological expansions include the RNAutomation™ mRNA service, NanoAb™ services, and nanoCAR-T mRNA solutions. The company supports academic and industrial researchers across multidisciplinary fields with integrated assay development and advanced bioreagent tools.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| 115年04月內部人持股異動(事後) | 2026-05-05 | Chinese | |
| 115年04月董事會成員及持股 | 2026-05-05 | Chinese | |
| 115年年報及股東會資料 — 2026_4133_20260529F02.pdf | 2026-04-27 | Chinese | |
| 115年年報及股東會資料 — 2026_4133_20260529F13.pdf | 2026-04-27 | Chinese | |
| 115年年報及股東會資料 — 2026_4133_20260529FE2.pdf | 2026-04-27 | Chinese | |
| 115年年報及股東會資料 — 2026_4133_20260529FE1.pdf | 2026-04-27 | English |
| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2026
15 filings
| |||||
| 41460733 | 115年04月內部人持股異動(事後) | 2026-05-05 | Chinese | ||
| 41458395 | 115年04月董事會成員及持股 | 2026-05-05 | Chinese | ||
| 37326076 | 115年年報及股東會資料 — 2026_4133_20260529F02.pdf | 2026-04-27 | Chinese | ||
| 37325954 | 115年年報及股東會資料 — 2026_4133_20260529F13.pdf | 2026-04-27 | Chinese | ||
| 37326464 | 115年年報及股東會資料 — 2026_4133_20260529FE2.pdf | 2026-04-27 | Chinese | ||
| 37274664 | 115年年報及股東會資料 — 2026_4133_20260529FE1.pdf | 2026-04-27 | English | ||
| 37274646 | 115年年報及股東會資料 — 2026_4133_20260529F01.pdf | 2026-04-27 | Chinese | ||
| 33993210 | 115年3月背書保證與資金貸與 | 2026-04-10 | Chinese | ||
| 33991866 | 115年3月營業收入 | 2026-04-10 | Chinese | ||
| 34543552 | 115年03月內部人持股異動(事後) | 2026-04-02 | Chinese | ||
| 34543547 | 115年03月董事會成員及持股 | 2026-04-02 | Chinese | ||
| 34543557 | 115年04月僑外投資持股 | 2026-04-01 | Chinese | ||
| 34543564 | 115年2月營業收入 | 2026-03-10 | Chinese | ||
| 34543561 | 115年2月背書保證與資金貸與 | 2026-03-10 | Chinese | ||
| 34543571 | 115年02月董事會成員及持股 | 2026-03-03 | Chinese | ||
Market data
Market data not available
Price history
Peer group · Research and experimental development on natural sciences and engineering
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
Genxone Spolka Akcyjna
A biotechnology company specializing in Next Generation Seq…
|
GX1 | PL | Professional, scientific and te… |
|
GeoVax Labs, Inc.
Clinical-stage biotech developing vaccines and therapies fo…
|
GOVX | US | Professional, scientific and te… |
|
GH Research PLC
Develops mebufotenin-based therapies for psychiatric and ne…
|
GHRS | IE | Professional, scientific and te… |
|
GI Innovation Inc.
Researches and develops protein-based drugs for immuno-onco…
|
358570 | KR | Professional, scientific and te… |
|
Ginkgo Bioworks Holdings, Inc.
Operates a horizontal platform for cell programming and syn…
|
DNA | US | Professional, scientific and te… |
|
GRAIL, Inc.
A healthcare company developing blood tests for multi-cance…
|
GRAL | US | Professional, scientific and te… |
|
GT Biopharma, Inc.
Clinical-stage immuno-oncology company developing therapies…
|
GTBP | US | Professional, scientific and te… |
|
Guard Therapeutics International AB
Clinical-stage biotech developing therapies to prevent acut…
|
GUARD | SE | Professional, scientific and te… |
|
Gubra A/S
Biotech and CRO focused on peptide drugs for metabolic and …
|
GUBRA | DK | Professional, scientific and te… |
|
HALOZYME THERAPEUTICS, INC.
Biopharmaceutical firm licensing technology to convert IV d…
|
HALO | US | Professional, scientific and te… |
Abnova (Taiwan) Corporation via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/52384/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=52384 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=52384 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
cURL
$ curl https://api.financialreports.eu/api/filings/?company=52384 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 52384}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for Abnova (Taiwan) Corporation (id: 52384)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.